The primary structure of the NH2terminally extended somatostatins isolated from ovine hypothalamic extracts, one containing 28 residues and the other 25, has been determined. The structure of somatostatin-28 is Ser-AlaAsn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-GlyCys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cts-OH; the shorter one, somatostatin-25, has the same sequence as somatostatin-28 except that the first three NH2-terminal residues are deleted. The two peptides as isolated were found to be oxidized at the methionine residue to the methionine sulfoxide. Their structures were established by subjecting the native peptides to direct sequence analysis in a Beckman 890C sequencer and identifying the released phenylthiohydantoin derivatives by high-performance liquid chromatography. Their structures were confirmed by trypsin digestion and isolation of all the tryptic peptides, followed by amino acid analysis of the tryptic fragments. Moreover, some of the tryptic peptides were matched with their respective synthetic replicates on high-performance liquid chromatography.
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The tetradecapeptide somatostatin was first isolated and characterized from ovine hypothalamus (1) on the basis of its ability to inhibit the secretion of growth hormone from primary cultures of dispersed rat anterior pituitary cells. The identical tetradecapeptide was subsequently isolated and characterized from porcine hypothalamus (2) as well as pigeon (3) and anglerfish (4) pancreases. In addition, several laboratories (2, 3, (5) (6) (7) (8) have observed, in the hypothalamic and pancreatic extracts, bioactive and immunoreactive somatostatin-like substances having molecular weights larger than the tetradecapeptide. Pradayrol et al. (9) reported the isolation (from porcine intestinal extracts) and primary structure of an NH2-terminally extended somatostatin containing 28 amino acids which was designated SS-28. We have also isolated two bioactive somatostatins containing 28 and 25 residues from ovine hypothalamic extracts. The primary structure of the larger ovine hypothalamic somatostatin is Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-AlaPro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe -Phe -TrpLys-Thr-Phe-Thr-Ser-Cys-OH, which is identical to the structure of the intestinal SS-28 isolated by Pradayrol et al. (9) . The shorter ovine hypothalamic peptide, SS-25, has the same structure as SS-28 except that the first three NH2-terminal residues are deleted.
We report here in detail the determination of the primary structure of the two larger hypothalamic somatostatins.
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MATERIALS AND METHODS The starting material for the isolation work was the combined Sephadex G-25 excluded fractions from extracts of 350,000 ovine hypothalami used in our purification of the thyrotropin-releasing factor (10) . Details of the isolation procedure will be published elsewhere. Briefly, the excluded fractions as above were combined and lyophilized and the resulting residue was passed through an anti-somatostatin affinity column. The retained somatostatin-like substances were eluted from the column with 0.025 M HCl; the column fractions were monitored by both an in vitro bioassay (1) and a somatostatin radioimmunoassay (3). The recovered somatostatin activities were then chromatographed on a Sephadex G-50 (fine) column to separate them according to molecular size. Essentially only one somatostatin-active zone with an apparent molecular weight of 3000 was recovered from the gel filtration column. This material was further purified by cation-exchange chromatography, whereupon two peaks of somatostatin-like activity were recovered. The faster eluting peak was subsequently purified by high-performance liquid chromatography (HPLC) to yield approximately 10 nmol of SS-28; the slower peak was similarly purified to yield about 30 nmol of SS-25.
Amino Acid Analyses. Peptides were hydrolyzed in sealed evacuated tubes containing 6 M HCI and 2% thioglycollic acid (11) for 24 hr at 1100C. To quantitate cysteine, peptide samples were oxidized with performic acid (12) and then hydrolyzed in 6 M HC1 only. Amino acid analyses of 50-100 pmol of peptide hydrolysate were performed with a Liquimat III amino acid analyzer (Kontron, Zurich, Switzerland) equipped with a proline conversion fluorescence detection system (13 subjected to three degradative cycles prior to the addition of the somatostatin peptides (17) . The recovered anilinothiazolinone derivatives of the released amino acids were converted to their respective phenylthiohydantoin (>PhNCS) derivatives by incubation with 1 M HC1 at 80°C for 10 min (18) . HPLC Analyses of the >PhNCS-Derivatives. The >PhNCS amino acid derivatives from the Edman degradations, were analyzed with a Spectra-Physics SP-8000 HPLC system. >PhNCS amino acid standards and HPLC solvents were obtained from Burdick and Jackson (Muskegon, MI) and Pierce Chemical, respectively. Two different >PhNCS amino acid analysis programs ( Fig. 1 A and B) were used to identify and confirm the identity of each residue. The >PhNCS amino acid derivatives of norleucine and the -y-methyl ester of glutamate (>PhNCS-GluOMe) were used as internal standards in all analyses with the Zorbax CN program (Fig. 1A) ; the /3-methyl ester of >PhNCS aspartate (>PhNCS-AspOMe) was used as the internal standard for the Zorbax ODS program (Fig. 1B) . >PhNCS-GluOMe and >PhNCS-AspOMe were synthesized according to Edman (18) except that the anilinothiozolinine derivatives were converted with 1 M HC1 in MeOH for 10 min at 50°C to their >PhNCS amino acids. The resolution of the >PhNCS amino acids obtained with these programs, the use of internal standards in all analyses, and the use of the ODS program to confirm the results obtained with the CN program permitted the unequivocal identification of the Edman degradation products. (Brownlee) . Gradient elution at a flow rate of 0.6 ml/min was accomplished with a pyridine formate/n-propanol buffer system (19) at room temperature as described in the legends to Figs. 4 and 5. The column effluent was collected in 1.8-ml fractions and monitored with an automatic fluorescamine detection system as described (20) .
RESULTS AND DISCUSSION Somatostatin-28. Amino acid analyses of the isolated ovine hypothalamic SS-28 gave the amino acid composition shown in Table 1 . All of the amino acids present in SS-14 were found within the composition of SS-28. Because the isolation of SS-28 was based on its somatostatin bioactivity as well as its immunoreactivity, these properties together with the amino acid composition imply that the sequence of SS-14 is contained within SS-28.
Direct sequence determination of approximately 4 nmol of the hypothalamic SS-28, using Polybrene as a carrier and our newly developed HPLC procedure for >PhNCS amino acid analyses, yielded the partial sequence: Ser-Ala-Asn-X-Asn Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-X-Lys-AsnPhe-Phe-Trp-Lys-X-Phe-X-X-X (Table 2) . Thus, ovine hypothalamic SS-28 is an NH-terminally extended peptide of SS-14. Furthermore, aside from the unknown residue at position 4, the NH2-terminal region of ovine SS-28 is identical to the porcine intestinal SS-28 reported by Pradayrol et al. (9) . The sequence data from the COOH-terminal region of hypothalamic SS-28 did not give an unequivocal sequence. However, the bioactivity, the immunoreactivity, and the amino acid composition all suggest that the COOH terminus of ovine SS-28 corresponds to that of SS-14.
Based on this assumption we have synthesized ovine hypothalamic SS-28 by solid-phase method (21) Time, min  FIG. 3 . HPLC chromatogram of the trypsin digestion products from ovine SS-28. The column was eluted isocratically for 30 min with a solvent composed of 60 ml of formic acid, 29 ml of pyridine, and 1% n-propanol made up to 1 liter with H20, followed by a 25-min linear gradient from 1% to 22% n-propanol and then isocratically at 22% n-propanol for 15 min, followed a column wash with 60% n-propanol; the same concentrations of formic acid and pyridine were maintained throughout the analysis. structure of the synthetic ovine SS-28 was verified independently by rigorous chemical analyses (21) .
When native SS-28 was compared with the synthetic material on HPLC under identical conditions, the native substance eluted a few minutes earlier than the synthetic peptide (data not shown). However, this discrepancy could be accounted for by assuming that the methionine residue in the native substance was oxidized to either methionine sulfoxide or methionine sulfone. A tryptic digest of 3 nmol of native SS-28 was subjected to HPLC; this yielded five major peptides (T1 to T5) (Fig. 3) . Amino acid analyses of these peptides gave results (Table 3) consistent with the theoretical compositions of the tryptic peptides from ovine SS-28 as shown in Fig. 2 . Furthermore, the retention times of peptides T1, T2, and T5 match the retention times of their respective tryptic fragments from synthetic SS-28. The presence of two cysteine residues in peptide T2 implies that ovine hypothalamic SS-28 as isolated is in the disulfide form. Peptide T4 was not found in the digest of the synthetic material. However, in subsequent experiments with synthetic S5-28, we found that SS-14 was one of the major fragments recovered from tryptic digestions using 3 nmol or less of substrate. Peptide T3 eluted earlier than the corresponding tryptic fragment from synthetic SS-28. The difference is probably due to the oxidation of the methionine residue in the native SS-28 to methionine sulfoxide during the isolation process. If the methionine residue had been oxidized to methionine sulfone, then it would not have been reduced to methionine with 2% thioglycollic acid prior to amino acid analysis.
To investigate this anomaly further, we synthesized SS-28-(1-11) by solid-phase methods (21) , substituting the methionine sulfoxide for methionine. The retention times of the synthetic [Met(0)8]SS-28-(1-11) and the native tryptic fragment T3 were the same (Fig. 3) under identical HPLC chromatographic conditions. Thus, the direct sequence determination of the intact, native SS-28 and the amino acid analyses of its tryptic fragments gave results consistent with the primary structure of ovine SS-28 as shown in Fig. 2 10 nmol of ovine hypothalamic SS-25 was analyzed directly in the Beckman 890C sequencer. From the sequence data shown in Table 4 a partial sequence Ser-Asn-Pro-Ala-Met-Ala-ProArg-Glu-Arg-Lys-Ala-Gly-X-Lys-Asn-Phe-Phe-Trp-X-X-Phe-X-X-X could be deduced. Thus, the NH2-terminal sequences of ovine SS-25 and SS-28 are identical except that the first three amino acids are deleted in the SS-25. The partial sequence analysis, amino acid composition, bioactivity, and immunoreactivity of ovine SS-25 suggest that the COOH-terminal part of the native molecule is identical to SS-14. Thus, ovine hypothalamic SS-25 is also an NH2-terminally extended peptide of SS-14.
We synthesized ovine SS-25 by solid-phase methods according to the structure shown in Fig. 4 . However, as with SS-28, the synthetic material eluted a few minutes later than the native substance under identical HPLC conditions (data not shown). Again, this disagreement may be due to the oxidation of the methionine residue in the native peptide to methionine sulfoxide during the isolation process.
A tryptic digest of 5 nmol of the native SS-25 was subjected to HPLC; it yielded four major peptide peaks as shown in (Fig.  5) . Amino acid analyses of the recovered peptides, TI to TiV (Table 5 ) gave results consistent with the theoretical compositions of the tryptic peptides of SS-25 as shown in Fig. 4 . Fur- 5 ). Thus, the sequence of the intact, native SS-25 by direct analyses and the amino acid compositions of its tryptic peptides are consistent with the structure of ovine hypothalamic SS-25 as shown in Fig. 4 .
In conclusion, we have isolated and characterized two somatostatins, from ovine hypothalamic extracts, containing 28 and 25 amino acids. As isolated, both peptides contain an intact disulfide bridge and are oxidized at the methionine residue to methionine sulfoxide. The structure of ovine hypothalamic SS-28 is identical to that of porcine intestinal SS-28 reported by Pradayrol et al. (9) ; the ovine SS-25 has the same sequence as SS-28 except for the first three NH2-terminal residues which are deleted. We cannot rule out the possibility that SS-25 is an artifactual product generated from the larger SS-28 during the tedious isolation process. In other publications (22, 23) , we have shown that synthetic SS-28 and SS-25 have greater specific activity than SS-14 to inhibit the secretion of growth hormone, in vitro or in vivo. The tetradecapeptide originally isolated is thus to be considered as a biologically active fragment of a larger molecule with greater specific activity.
